Traded Jun 2, 2026 · largest single transaction ~$10.8MNot reported under a pre-arranged trading plan
Show all 2 transactions
Jun 2, 2026~$10.8M · 4.62M sh @ $2.35
DetailsOfficial recordJun 2, 2026~$902K · 384K sh @ $2.35
DetailsOfficial record
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
NAUT · NASDAQ · Laboratory Analytical Instruments
Nautilus Biotechnology (NAUT) · oqro.io/stocks/NAUT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.12−0.05 (−2.30%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
12 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Traded Jun 2, 2026 · largest single transaction ~$10.8MNot reported under a pre-arranged trading plan
Jun 2, 2026~$10.8M · 4.62M sh @ $2.35
DetailsOfficial recordJun 2, 2026~$902K · 384K sh @ $2.35
DetailsOfficial recordInsider buying
Traded Mar 4 · filed the same day
Since the trade −19.1% · S&P 500 +0.7% · to Nov 20
Bought 9% below the 52-week high, RSI 57, 96% above its 200-day average, 32 points ahead of the S&P 500 over 3 months
The CEO of Nautilus Biotechnology paid $65K out of pocket for Nautilus Biotechnology shares.
Insider buying
Their first buy on recordTraded Nov 6, 2025 · filed 5 days later
Since the trade +40.4% · S&P 500 +2.9% · to Nov 20
Bought 43% below the 52-week high, RSI 59, 58% above its 200-day average, 101 points ahead of the S&P 500 over 3 months
Traded Sep 5 – Sep 8, 2025 · largest single transaction ~$79K
Sep 5, 2025~$79K · 117K sh @ $0.6742
DetailsOfficial recordInsider buying
First buy since 2022Traded Sep 4, 2025 · filed 1 day later
Since the trade +225.3% · S&P 500 +6.3% · to Nov 20
Nautilus Biotechnology's General Counsel paid $13K out of pocket for Nautilus Biotechnology shares. 1 other person at Nautilus Biotechnology bought some too, in the same month. Shares held went up 37% with this purchase.
Traded May 8 – May 12, 2025 · largest single transaction ~$8.8K
May 8, 2025~$8.8K · 12K sh @ $0.7323
DetailsOfficial recordTraded Mar 19 – Mar 20, 2025 · largest single transaction ~$53K
Mar 19, 2025~$53K · 53K sh @ $0.9949
DetailsOfficial recordSep 8, 2025~$57K · 84K sh @ $0.683
DetailsOfficial recordMay 12, 2025~$1.1K · 1,500 sh @ $0.7317
DetailsOfficial recordMar 20, 2025~$24K · 24K sh @ $0.9982
DetailsOfficial record1 open-market purchase and 2 open-market sales by insiders of NAUT between Jan 27, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Oct 27, 2026. The data provider lists the next release for Feb 24, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Oct 27, 2026 | None | None | None |
| Jul 28, 2026 | None | None | None |
| Apr 28, 2026 | None | None | None |
| Feb 26, 2026 | None | None | 1 purchase |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies